Skip to main content
Top
Published in: Acta Neuropathologica 2/2010

01-08-2010 | Original Paper

Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment

Authors: Anna Gomez, Isidre Ferrer

Published in: Acta Neuropathologica | Issue 2/2010

Login to get access

Abstract

Previous studies have shown altered synuclein, increased oxidative stress damage and increased oxidative stress responses in patients with sporadic Parkinson’s disease (PD) without cognitive impairment. Yet no information exists about possible molecular alterations in the cerebral cortex in familial PD. The present study shows abnormal α-synuclein solubility and aggregation, and aggregated nitrated α-synuclein, in the cerebral cortex (area 8) in cases with long-lasting PD linked with the G2019S LRRK2 mutation, one of them with a few Lewy bodies (LBs) and the other two without LBs in the cerebral cortex. Increased expression of the oxidative stress marker malondialdehyde-lysine (MDAL), together with increased oxidative stress responses, AGE receptors (RAGE) and superoxide dismutase 2, occurred in the frontal cortex in the three LRRK2 cases compared with three controls processed in parallel. Bi-dimensional gel electrophoresis, western blotting, in-gel digestion and mass spectrometry disclosed glial fibrillary acidic protein as a target of MDAL adducts. Tubulin β4 and enolase 2 were also identified as targets of oxidative damage. These results demonstrate biochemical abnormalities of α-synuclein, and increased oxidative stress damage and oxidative stress responses in the frontal cortex in PD linked with G2019S LRRK2 mutation not related with the presence of cortical LBs and in the absence of apparent cognitive deficits. These findings show that the cerebral cortex in familial PD linked with G2019S LRRK2 is affected in a similar way than that seen in sporadic PD without cognitive impairment.
Literature
1.
go back to reference Anderson JP, Walker DE, Goldstein JM, Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chartaway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ (2006) Phosphorylation of Ser 129 is the dominant pathological modification of synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739–29759CrossRefPubMed Anderson JP, Walker DE, Goldstein JM, Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chartaway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ (2006) Phosphorylation of Ser 129 is the dominant pathological modification of synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739–29759CrossRefPubMed
2.
go back to reference Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, Ikeda K, Kawai M (1999) Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson’s disease and in dementia with Lewy bodies. Brain Res 843:53–61CrossRefPubMed Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, Ikeda K, Kawai M (1999) Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson’s disease and in dementia with Lewy bodies. Brain Res 843:53–61CrossRefPubMed
3.
go back to reference Baba M, Nakajo S, Tu PH, Tomita T, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol 152:879–884PubMed Baba M, Nakajo S, Tu PH, Tomita T, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol 152:879–884PubMed
4.
go back to reference Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibañez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Ooostra BA, Heutink P (2003) Mutations in DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256–259CrossRefPubMed Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibañez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Ooostra BA, Heutink P (2003) Mutations in DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256–259CrossRefPubMed
5.
go back to reference Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMed Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMed
6.
go back to reference Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMed Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMed
7.
go back to reference Braak H, Sandmann-Keil D, Gai W, Braak E (1999) Extensive axonal Lewy neurites in Parkinson’s disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci Lett 265:67–69CrossRefPubMed Braak H, Sandmann-Keil D, Gai W, Braak E (1999) Extensive axonal Lewy neurites in Parkinson’s disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci Lett 265:67–69CrossRefPubMed
8.
go back to reference Butterfield DA, Sultana R, Poon HF (2006) Redox proteomics: a new approach to investigate oxidative stress in Alzheimer’s disease. In: Dalle-Donne I, Scaloni A, Butterfield DA (eds) Redox proteomics: from protein modifications to cellular dysfunction and diseases. Wiley, New Jersey, pp 563–603 Butterfield DA, Sultana R, Poon HF (2006) Redox proteomics: a new approach to investigate oxidative stress in Alzheimer’s disease. In: Dalle-Donne I, Scaloni A, Butterfield DA (eds) Redox proteomics: from protein modifications to cellular dysfunction and diseases. Wiley, New Jersey, pp 563–603
9.
go back to reference Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases. J Biol Chem 279:13256–13264CrossRefPubMed Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases. J Biol Chem 279:13256–13264CrossRefPubMed
10.
go back to reference Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L (2005) Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280:11648–11655CrossRefPubMed Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L (2005) Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280:11648–11655CrossRefPubMed
11.
go back to reference Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE, Gearing M, Levey AI, Chin LS, Li L (2006) Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 281:10816–10824CrossRefPubMed Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE, Gearing M, Levey AI, Chin LS, Li L (2006) Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 281:10816–10824CrossRefPubMed
12.
go back to reference Chung KKK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, Dawson TM (2004) S-nitrosylation of parkin regulates ubiquitination and compromises Parkin’s protective function. Science 304:1328–1331CrossRefPubMed Chung KKK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, Dawson TM (2004) S-nitrosylation of parkin regulates ubiquitination and compromises Parkin’s protective function. Science 304:1328–1331CrossRefPubMed
13.
go back to reference Dalfó E, Gómez-Isla T, Rosa JL, Nieto Bodelón M, Cuadrado Tejedor M, Barrachina M, Ambrosio S, Ferrer I (2004) Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. J Neuropathol Exp Neurol 63:302–313PubMed Dalfó E, Gómez-Isla T, Rosa JL, Nieto Bodelón M, Cuadrado Tejedor M, Barrachina M, Ambrosio S, Ferrer I (2004) Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. J Neuropathol Exp Neurol 63:302–313PubMed
14.
go back to reference Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816–830CrossRefPubMed Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816–830CrossRefPubMed
15.
16.
go back to reference Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, Stern MB, Gollomp SM, Ischiropoulos H, Lee VM, Trojanowski JQ (2000) Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 157:1439–1445PubMed Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, Stern MB, Gollomp SM, Ischiropoulos H, Lee VM, Trojanowski JQ (2000) Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 157:1439–1445PubMed
17.
go back to reference El-Agnaf OM, Jakes R, Curran MD, Wallace A (1998) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson’s disease. FEBS Lett 440:67–70CrossRefPubMed El-Agnaf OM, Jakes R, Curran MD, Wallace A (1998) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson’s disease. FEBS Lett 440:67–70CrossRefPubMed
18.
go back to reference Elbaz A (2008) LRRK2: bridging the gap between sporadic and hereditary Parkinson’s disease. Lancet Neurol 7:562–564CrossRefPubMed Elbaz A (2008) LRRK2: bridging the gap between sporadic and hereditary Parkinson’s disease. Lancet Neurol 7:562–564CrossRefPubMed
19.
go back to reference Ferrer I (2009) Early involvement of the cerebral cortex in Parkinson disease: convergence of multiple metabolic defects. Prog Neurobiol 88:89–103CrossRefPubMed Ferrer I (2009) Early involvement of the cerebral cortex in Parkinson disease: convergence of multiple metabolic defects. Prog Neurobiol 88:89–103CrossRefPubMed
20.
go back to reference Ferrer I, Martinez A, Boluda S, Parchi P, Barrachina M (2008) Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank 9:181–194CrossRefPubMed Ferrer I, Martinez A, Boluda S, Parchi P, Barrachina M (2008) Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank 9:181–194CrossRefPubMed
21.
22.
go back to reference Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164CrossRefPubMed Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164CrossRefPubMed
23.
go back to reference Gaig C, Ezquerra M, Marti MJ, Vallderiola F, Muñoz E, Lladó A, Rey MJ, Cardozo A, Molinuevo JL, Tolosa E (2008) Screening for the LRRK2 G2019S and codon1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 270:94–98CrossRefPubMed Gaig C, Ezquerra M, Marti MJ, Vallderiola F, Muñoz E, Lladó A, Rey MJ, Cardozo A, Molinuevo JL, Tolosa E (2008) Screening for the LRRK2 G2019S and codon1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 270:94–98CrossRefPubMed
24.
go back to reference Gaig C, Marti MJ, Ezquerra M, REy MJ, Cardozo A, Tolosa E (2007) G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies. J Neurol Neurosurg Psychiatr 78:626–628CrossRefPubMed Gaig C, Marti MJ, Ezquerra M, REy MJ, Cardozo A, Tolosa E (2007) G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies. J Neurol Neurosurg Psychiatr 78:626–628CrossRefPubMed
25.
go back to reference Galvin JE, Lee VM, Trojanowski JQ (2001) Synucleinopathies: clinical and pathological implications. Arch Neurol 58:186–190CrossRefPubMed Galvin JE, Lee VM, Trojanowski JQ (2001) Synucleinopathies: clinical and pathological implications. Arch Neurol 58:186–190CrossRefPubMed
26.
go back to reference Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropuolos H, Trojanowski JQ, Lee VMY (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290:985–989CrossRefPubMed Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropuolos H, Trojanowski JQ, Lee VMY (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290:985–989CrossRefPubMed
27.
go back to reference Gómez A, Ferrer I (2009) Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J Neurosci Res 87:1002–1013CrossRefPubMed Gómez A, Ferrer I (2009) Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J Neurosci Res 87:1002–1013CrossRefPubMed
28.
go back to reference Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E (1999) Oxidative stress induces amyloid-like aggregates formation of NACP/α-synuclein in vitro. NeuroReport 10:717–721CrossRefPubMed Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E (1999) Oxidative stress induces amyloid-like aggregates formation of NACP/α-synuclein in vitro. NeuroReport 10:717–721CrossRefPubMed
29.
go back to reference Hashimoto M, Masliah E (1999) α-Synuclein in Lewy body disease and Alzheimer’s disease. Brain Pathol 9:707–720PubMed Hashimoto M, Masliah E (1999) α-Synuclein in Lewy body disease and Alzheimer’s disease. Brain Pathol 9:707–720PubMed
30.
go back to reference Iwatsubo T (2003) Aggregation of α-synuclein in the pathogenesis of Parkinson’s disease. J Neurol 250(Suppl 3):11–14 Iwatsubo T (2003) Aggregation of α-synuclein in the pathogenesis of Parkinson’s disease. J Neurol 250(Suppl 3):11–14
31.
go back to reference Jellinger KA (2008) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116:1–16CrossRefPubMed Jellinger KA (2008) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116:1–16CrossRefPubMed
32.
go back to reference Jellinger K, Mizuno Y (2003) Parkinson’s disease. In: Dickson D (ed) Neurodegeneration: the molecular pathology of dementia and movement disorders. ISN Neuropath Press, Basel, pp 159–187 Jellinger K, Mizuno Y (2003) Parkinson’s disease. In: Dickson D (ed) Neurodegeneration: the molecular pathology of dementia and movement disorders. ISN Neuropath Press, Basel, pp 159–187
33.
go back to reference Kahle PJ, Newmann M, Ozmen L, Mülkler V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C (2001) Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159:2215–2225PubMed Kahle PJ, Newmann M, Ozmen L, Mülkler V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C (2001) Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159:2215–2225PubMed
34.
go back to reference Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605–608CrossRefPubMed Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605–608CrossRefPubMed
35.
go back to reference Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, Pirttilä T (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer’s disease and aging brain. Neurobiol Dis 20:858–870CrossRefPubMed Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, Pirttilä T (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer’s disease and aging brain. Neurobiol Dis 20:858–870CrossRefPubMed
36.
go back to reference Krüger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat Genet 18:106–108CrossRefPubMed Krüger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat Genet 18:106–108CrossRefPubMed
37.
go back to reference Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395:451–452CrossRefPubMed Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395:451–452CrossRefPubMed
38.
go back to reference Li J, Uversky VN, Fink AL (2001) Effects of familial Parkinson’s disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 40:11604–11613CrossRefPubMed Li J, Uversky VN, Fink AL (2001) Effects of familial Parkinson’s disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 40:11604–11613CrossRefPubMed
39.
go back to reference Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease. Nat Neurosci 12:826–828CrossRefPubMed Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease. Nat Neurosci 12:826–828CrossRefPubMed
40.
go back to reference Martínez A, Portero-Otin M, Pamplona R, Ferrer I (2009) Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 2010; Epub ahead of print Martínez A, Portero-Otin M, Pamplona R, Ferrer I (2009) Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 2010; Epub ahead of print
41.
go back to reference Martínez A, Carmona M, Portero-Otin M, Naudí A, Pamplona R, Ferrer I (2008) Type-dependent oxidative damage in frontotemporal lobar degeneration: cortical astrocytes are targets of oxidative damage. J Neuropathol Exp Neurol 67:1122–1136CrossRefPubMed Martínez A, Carmona M, Portero-Otin M, Naudí A, Pamplona R, Ferrer I (2008) Type-dependent oxidative damage in frontotemporal lobar degeneration: cortical astrocytes are targets of oxidative damage. J Neuropathol Exp Neurol 67:1122–1136CrossRefPubMed
42.
go back to reference Martí-Massó JF, Ruiz-Martinez J, Bolaño MJ, Ruiz I, Gorostidi A, Moreno F, Ferrer I, López de Munain A (2009) Neuropathology of Parkinson disease with the R1441G mutation in LRRK2. Mov Disord (accepted) Martí-Massó JF, Ruiz-Martinez J, Bolaño MJ, Ruiz I, Gorostidi A, Moreno F, Ferrer I, López de Munain A (2009) Neuropathology of Parkinson disease with the R1441G mutation in LRRK2. Mov Disord (accepted)
43.
go back to reference Muntané G, Dalfó E, Martínez A, Rey MJ, Avila J, Pérez M, Portero M, Pamplona R, Ayala V, Ferrer I (2006) Glial fibrillary acidic protein is a major target of glycoxidative and lipoxidative damage in Pick’s disease. J Neurochem 99:177–185CrossRefPubMed Muntané G, Dalfó E, Martínez A, Rey MJ, Avila J, Pérez M, Portero M, Pamplona R, Ayala V, Ferrer I (2006) Glial fibrillary acidic protein is a major target of glycoxidative and lipoxidative damage in Pick’s disease. J Neurochem 99:177–185CrossRefPubMed
44.
go back to reference Neumann M, Kahle PJ, Giassonb BI, Ozmen L, Borroni E, Spoore W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar H, Haass C (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 110:1429–1439PubMed Neumann M, Kahle PJ, Giassonb BI, Ozmen L, Borroni E, Spoore W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar H, Haass C (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 110:1429–1439PubMed
45.
go back to reference Paik SR, Shin HJ, Lee JM (2000) Metal-catalyzed oxidation of α-synuclein in the presence of copper(II) and hydrogen peroxide. Arch Biochem Biophys 378:269–277CrossRefPubMed Paik SR, Shin HJ, Lee JM (2000) Metal-catalyzed oxidation of α-synuclein in the presence of copper(II) and hydrogen peroxide. Arch Biochem Biophys 378:269–277CrossRefPubMed
46.
go back to reference Paisanz-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Grug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martínez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, Singletomn AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44:595–600CrossRef Paisanz-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Grug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martínez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, Singletomn AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44:595–600CrossRef
47.
go back to reference Pamplona R, Dalfó E, Ayala V, Bellmunt MJ, Prat J, Ferrer I, Portero-Otín M (2005) Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 280:21522–21530CrossRefPubMed Pamplona R, Dalfó E, Ayala V, Bellmunt MJ, Prat J, Ferrer I, Portero-Otín M (2005) Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 280:21522–21530CrossRefPubMed
48.
go back to reference Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) α-Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91CrossRefPubMed Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) α-Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91CrossRefPubMed
49.
go back to reference Parkkinen L, Pirttilä T, Alafuzoff I (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115:399–407CrossRefPubMed Parkkinen L, Pirttilä T, Alafuzoff I (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115:399–407CrossRefPubMed
50.
go back to reference Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VM, Ischiropoulos H (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 21:8053–8061PubMed Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VM, Ischiropoulos H (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 21:8053–8061PubMed
51.
go back to reference Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047CrossRefPubMed Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047CrossRefPubMed
52.
go back to reference Rajput A, Dickson DW, Robinson CA, Ross OA, Dächael JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67:1506–1508CrossRefPubMed Rajput A, Dickson DW, Robinson CA, Ross OA, Dächael JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67:1506–1508CrossRefPubMed
53.
go back to reference Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated α-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644–654PubMed Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated α-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644–654PubMed
54.
go back to reference Santpere G, Ferrer I (2008) Delineation of progressive supranuclear palsy-like pathology. Astrocytes in striatum are primary targets of tau phosphorylation and GFAP oxidation. Brain Pathol 19:177–187CrossRefPubMed Santpere G, Ferrer I (2008) Delineation of progressive supranuclear palsy-like pathology. Astrocytes in striatum are primary targets of tau phosphorylation and GFAP oxidation. Brain Pathol 19:177–187CrossRefPubMed
55.
56.
57.
go back to reference Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E (2008) Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 45:667–678CrossRefPubMed Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E (2008) Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 45:667–678CrossRefPubMed
58.
go back to reference Spillantini MG, Schmidt M, Lee VM, Trojanowski JQ, Kaques R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840CrossRefPubMed Spillantini MG, Schmidt M, Lee VM, Trojanowski JQ, Kaques R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840CrossRefPubMed
59.
go back to reference Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469–6473CrossRefPubMed Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469–6473CrossRefPubMed
60.
go back to reference Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, Gasser T, Wszolek Z, Muller T, Bornemann A, Wolburg H, Downward J, Riess O, Schulz JB, Kruger R (2005) Loss of function mutations in the gene encoding Omi/HrtA2 in Parkinson’s disease. Hum Mol Genet 14:2099–2111CrossRefPubMed Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, Gasser T, Wszolek Z, Muller T, Bornemann A, Wolburg H, Downward J, Riess O, Schulz JB, Kruger R (2005) Loss of function mutations in the gene encoding Omi/HrtA2 in Parkinson’s disease. Hum Mol Genet 14:2099–2111CrossRefPubMed
61.
go back to reference Sultana R, Perluigi M, Butterfield DA (2009) Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 118:131–150CrossRefPubMed Sultana R, Perluigi M, Butterfield DA (2009) Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 118:131–150CrossRefPubMed
62.
go back to reference Takahashi M, Kanuka H, Fujiwara H, Koyama A, Hasegawa M, Miura M, Iwatsubo T (2003) Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci Lett 336:155–158CrossRefPubMed Takahashi M, Kanuka H, Fujiwara H, Koyama A, Hasegawa M, Miura M, Iwatsubo T (2003) Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci Lett 336:155–158CrossRefPubMed
63.
go back to reference Uversky VN (2007) Neuropathology, biochemistry, and biophysics of synuclein aggregation. J Neurochem 103:17–37PubMed Uversky VN (2007) Neuropathology, biochemistry, and biophysics of synuclein aggregation. J Neurochem 103:17–37PubMed
64.
go back to reference Uversky VN, Yamin G, Munishkina LA, Karymov MA, Millet IS, Doniach S, Lyubchenko YL, Fink AL (2005) Effects of nitration on the structure and aggregation of α-synuclein. Mol Brain Res 134:84–102CrossRefPubMed Uversky VN, Yamin G, Munishkina LA, Karymov MA, Millet IS, Doniach S, Lyubchenko YL, Fink AL (2005) Effects of nitration on the structure and aggregation of α-synuclein. Mol Brain Res 134:84–102CrossRefPubMed
65.
go back to reference Valente EM, Abou-Sleiman PM, Caputo V, Mugit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DC, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304:1158–1160CrossRefPubMed Valente EM, Abou-Sleiman PM, Caputo V, Mugit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DC, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304:1158–1160CrossRefPubMed
66.
go back to reference Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson’s disease. Neurosci Lett 249:180–182CrossRef Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson’s disease. Neurosci Lett 249:180–182CrossRef
67.
go back to reference Wakabayashi K, Tanji K, Mori F, Takahashi H (2007) The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of α-synuclein aggregates. Neuropathology 27:494–506CrossRefPubMed Wakabayashi K, Tanji K, Mori F, Takahashi H (2007) The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of α-synuclein aggregates. Neuropathology 27:494–506CrossRefPubMed
68.
go back to reference Wakamatsu M, Ishii A, Ukai Y, Sakagami J, Iwata S, Ono M, Matsumoto K, Nakamura A, Tada N, Kobayashi K, Iwatsubo T, Yoshimoto M (2007) Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J Neurosci Res 85:1819–1825CrossRefPubMed Wakamatsu M, Ishii A, Ukai Y, Sakagami J, Iwata S, Ono M, Matsumoto K, Nakamura A, Tada N, Kobayashi K, Iwatsubo T, Yoshimoto M (2007) Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J Neurosci Res 85:1819–1825CrossRefPubMed
69.
go back to reference Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, Strongosky AJ, Zimprich A, Müller-Myhsok B, Farrer MJ, Gasser T, Calne DB, Dickson DW (2004) Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62:1619–1622PubMed Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, Strongosky AJ, Zimprich A, Müller-Myhsok B, Farrer MJ, Gasser T, Calne DB, Dickson DW (2004) Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62:1619–1622PubMed
70.
go back to reference Yamin G, Uversky VN, Fink AL (2003) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett 542:147–152CrossRefPubMed Yamin G, Uversky VN, Fink AL (2003) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett 542:147–152CrossRefPubMed
71.
go back to reference Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, Uehara T, Lipton SA (2004) Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci 101:10810–10814CrossRefPubMed Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, Uehara T, Lipton SA (2004) Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci 101:10810–10814CrossRefPubMed
72.
go back to reference Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uiti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607CrossRefPubMed Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uiti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607CrossRefPubMed
73.
go back to reference Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodríguez O, Atares B, Llorens V, Gómez-Tortosa E, del Ser T, Muñoz DG, de Yébenes JG (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164–173CrossRefPubMed Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodríguez O, Atares B, Llorens V, Gómez-Tortosa E, del Ser T, Muñoz DG, de Yébenes JG (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164–173CrossRefPubMed
Metadata
Title
Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment
Authors
Anna Gomez
Isidre Ferrer
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 2/2010
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-010-0669-y

Other articles of this Issue 2/2010

Acta Neuropathologica 2/2010 Go to the issue